To investigate the specificity of the ELISA assays we included 54 serum samples that were collected before the COVID‐19 pandemic or from patients testing negative for COVID‐19 but confirmed with other bacterial, viral infections or autoimmune diseases. These samples had been stored frozen at −70°C. The samples included sera testing positive for Epstein‐Barr virus (n = 1), Cytomegalovirus (n = 4), Influenza A (n = 5), Influenza B (n = 6), Parainfluenza virus (n = 9), Mycoplasma pneumoniae (n = 3), Respiratory syncytial virus (n = 3), Borrelia burgdorferi (n = 6), Human granulocytic anaplasmosis (HGA) (n = 3), Treponema pallidum (n = 1), Rheumatoid arthritis (n = 3), Systemic lupus erythematosus (n = 1). Additionally, nine sera samples were obtained from patients with PCR‐confirmed human coronavirus infections, not SARS‐CoV‐2.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.